Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant Staphylococcus aureus

被引:11
|
作者
Doddangoudar, V. C. [1 ]
O'Donoghue, M. M. [2 ]
Chong, E. Y. C. [3 ]
Tsang, D. N. C. [3 ]
Boost, M. V. [1 ]
机构
[1] Hong Kong Polytech Univ, Dept Hlth Technol & Informat, Kowloon, Hong Kong, Peoples R China
[2] Hong Kong Polytech Univ, Sch Nursing, Kowloon, Hong Kong, Peoples R China
[3] Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China
关键词
VISA; two-component systems; vraSR; graSR; rpoB; INTERMEDIATE; STRAINS;
D O I
10.1093/jac/dks171
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Problems of vancomycin non-susceptible Staphylococcus aureus (VISA) and subsequent treatment failure are increasing. This study aimed to observe development and loss of vancomycin non-susceptibility, determine exposure time needed for resistance development, and follow mutations in the VraSR and GraSR two-component systems during these processes. Sequences of vraS, graR and rpoB, proposed as critical sites of mutation associated with non-susceptibility development, were compared in susceptible clinical methicillin-resistant S. aureus isolates both initially and following vancomycin induction and its withdrawal, to identify mutations. Mutations were correlated with exposure time, increase in vancomycin MIC and phenotypic changes. Both time required for heterogeneous VISA and VISA development, and maximum MIC attained (620 mg/L) varied between strains. Sequence analysis revealed the presence of stop codons in an initial strain with delayed non-susceptibility development. Other changes in vraS and graR occurred during VISA development in all isolates. After removal of vancomycin pressure, most strains reverted to susceptibility accompanied by emergence of stop codons in both vraS and graR. One strain not displaying stop codons remained resistant in the absence of vancomycin pressure. A substitution in GraR (D148Q) appeared to be associated with an elevated MIC (20 mg/L). No rpoB mutations were observed throughout VISA development. Vancomycin non-susceptibility developed in all strains tested. Mutations in vraS and graR appeared to be essential for VISA development, with stop codons playing an important role in delaying non-susceptibility development and reversion. Absence of mutations in rpoB suggests that these are not essential for vancomycin resistance. Further work is required to confirm consistent changes involved in non-susceptibility development.
引用
收藏
页码:2101 / 2106
页数:6
相关论文
共 50 条
  • [1] First isolation in Argentina of community-acquired methicillin-resistant Staphylococcus aureus with intermediate susceptibility to vancomycin and non-susceptibility to daptomycin
    Errecalde, Laura
    Ceriana, Paola
    Gagetti, Paula
    Erbin, Mariana
    Duarte, Andrea
    Rolon, Maria J.
    Cuatz, Daniel
    Corso, Alejandra
    Kaufman, Sara
    [J]. REVISTA ARGENTINA DE MICROBIOLOGIA, 2013, 45 (02): : 99 - 103
  • [2] Investigation of Mutations and Expression Level of GraSR and WalKR Systems Associated with Vancomycin Non-Susceptibility in Methicillin-Resistant Staphylococcus aureus
    Aghaei, Mahsa
    Asadpour, Leila
    Arasteh, Amir
    [J]. MOLECULAR GENETICS MICROBIOLOGY AND VIROLOGY, 2024, 39 (01) : 65 - 73
  • [3] Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages
    Howe, RA
    Monk, A
    Wootton, M
    Walsh, TR
    Enright, MC
    [J]. EMERGING INFECTIOUS DISEASES, 2004, 10 (05) : 855 - 857
  • [4] Methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in Taiwan
    Lin, Chien-Yu
    Wang, Jui-Hsing
    Lin, Kai-Hsiang
    Ho, Yu-Ling
    Ho, Cheng-Mao
    [J]. TZU CHI MEDICAL JOURNAL, 2018, 30 (03): : 135 - 140
  • [5] Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Canada
    Webster, Duncan
    Rennie, Robert P.
    Brosnikoff, Cheryl L.
    Chui, Linda
    Brown, Connie
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2007, 57 (02) : 177 - 181
  • [6] In vivo development of decreased susceptibility to vancomycin in clinical isolates of methicillin-resistant Staphylococcus aureus
    Sugino, Y
    Iinuma, Y
    Ichiyama, S
    Ito, Y
    Ohkawa, S
    Nakashima, N
    Shimokata, K
    Hasegawa, Y
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (03) : 159 - 167
  • [7] Reduced susceptibility to vancomycin of nosocomial isolates of methicillin-resistant Staphylococcus aureus
    Kantzanou, M
    Tassios, PT
    Tseleni-Kotsovili, A
    Legakis, NJ
    Vatopoulos, AC
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (05) : 729 - 731
  • [8] Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
    Hiramatsu, K
    Hanaki, H
    Ino, T
    Yabuta, K
    Oguri, T
    Tenover, FC
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (01) : 135 - 136
  • [9] Vancomycin Heteroresistance and Methicillin-Resistant Staphylococcus aureus
    Deresinski, Stan
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (05): : 605 - 609
  • [10] Trends in antimicrobial non-susceptibility in methicillin-resistant Staphylococcus aureus from Germany (2004-2011)
    Schaumburg, F.
    Idelevich, E. A.
    Peters, G.
    Mellmann, A.
    von Eiff, C.
    Becker, K.
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2014, 20 (09) : O554 - O557